Impaired Cellular and Antibody immunity after COVID-19 in Chronically Immunosuppressed Transplant Recipients

Authors

  • Chethan Ashokkumar
  • Vinayak Rohan
  • Alexander H Kroemer
  • Sohail Rao
  • George Mazariegos
  • Brandon W Higgs
  • Satish Nadig
  • Jose Almeda
  • Harmeet Dhani
  • Khalid Khan
  • Nada Yazigi
  • Udeme Ekong
  • Stuart Kaufman
  • Monica M Betancourt-Garcia
  • Kavitha Mukund
  • Pradeep Sethi
  • Shikhar Mehrotra
  • Kyle Soltys
  • Manasi S Singh
  • Geoffrey Bond
  • Ajai Khanna
  • Mylarappa Ningappa
  • Brianna Spishock
  • Elizabeth Sindhi
  • Neha Atale
  • Maggie Saunders
  • Prabhakar Baliga
  • Thomas Fishbein
  • Shankar Subramaniam
  • Rakesh Sindhi

Abstract

Assessment of cellular immunity to the SARS-CoV-2 coronavirus is of great interest in chronically immunosuppressed transplant recipients (Tr), who are predisposed to infections and vaccination failures. We evaluated CD154-expressing T-cells induced by spike (S) antigenic peptides in 204 subjects-103 COVID-19 patients and 101 healthy unexposed subjects. Sreactive CD154+T-cell frequencies were a) higher in 42 healthy unexposed Tr who were sampled pre-pandemic, compared with healthy NT (p=0.02), b) lower in Tr COVID-19 patients compared with healthy Tr (p<0.0001) and were accompanied by lower S-reactive B-cell frequencies (p<0.05), c) lower in Tr with severe COVID-19 (p<0.0001), or COVID-19 requiring hospitalization (p<0.05), compared with healthy Tr. Among Tr with COVID-19, cytomegalovirus co-infection occurred in 34%; further, incidence of anti-receptor-binding-domain IgG (p=0.011) was lower compared with NT COVID-19 patients. Healthy unexposed Tr exhibit pre-existing T-cell immunity to SARS-CoV-2. COVID-19 impairs anti-S T-cell and antibody and predisposes to CMV co-infection in transplant recipients.

Downloads

Published

2023-10-18